For the Inventor, By the Inventor

Enter assignee name

Horsham, PA, United States of America

Janssen Biotech, Inc.

USPTO Granted Patents = 416

CIPO Patents = 36

EPO Patents = 182

Trademarks = 8

Forward Citations = 1,891

Loading Chart...

Loading Chart...

632 inventors (with patents filed for the assignee):

Jinquan Luo (43 out of 51 patents)

Raymond W Sweet (38 out of 47 patents)

Steven Jacobs (36 out of 40 patents)

4. Sheng-Jiun Wu (32 out of 36 patents)

5. Alireza Rezania (31 out of 48 patents)

6. David M Knight (27 out of 101 patents)

7. Jill M Giles-Komar (27 out of 56 patents)

8. Alexey Teplyakov (26 out of 32 patents)

9. Bernard Scallon (25 out of 49 patents)

10. Mark Hilary Cunningham (25 out of 46 patents)

11. David J Shealy (24 out of 41 patents)

12. Karyn O'Neil (24 out of 39 patents)

13. Rajkumar Ganesan (22 out of 28 patents)

14. Michael Diem (20 out of 21 patents)

15. Sanjaya Singh (19 out of 71 patents)

Core Competencies:

Drug Delivery System

Lipidated Peptide Inhibitors

Bispecific Antibodies

Interleukin-23 Receptor

Anti-PD-1 Antibodies

Prostate Neoantigens

EGFR Inhibitors

Monoclonal Antibodies

Immune Targeting Molecules

Anti-TNF Antibodies

Raman Spectroscopy

Biotherapeutics

416 patents: Sort by Forward Citations

1. 12528869 - Treatment of Non-Small Cell Lung Cancer with EGFR Mutations (2026-01-20),

2. 12523661 - Materials and methods for differential characterization of molecular conjugates and conjugation (2026-01-13),

3. 12522658 - ANTI-CD79 CHIMERIC ANTIGEN RECEPTORS, CAR-T CELLS, AND USES THEREOF (2026-01-13),

4. 12522645 - BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA (2026-01-13),

5. 12492256 - Methods and Compositions for Modulating Beta Chain Mediated Immunity (2025-12-09),

6. 12492226 - MATERIALS AND METHODS FOR PRODUCING BIOENGINEERED VIRUS SPECIFIC LYMPHOCYTES (2025-12-09),

7. D1104254 - Drug delivery system (2025-12-02),

8. 12478617 - Lipidated peptide inhibitors of interleukin-23 receptor (2025-11-25),

9. D1102591 - Drug delivery system (2025-11-18),

10. 12460001 - Proteins comprising CD3 antigen binding domains and uses thereof (2025-11-04),

11. 12453785 - Macrocyclic chelators and methods of use thereof (2025-10-28),

12. 12448455 - Combination therapies with bispecific anti-EGFR/c-met antibodies and third generation EGFR tyrosine kinase inhibitors (2025-10-21),

13. 12448449 - Immune targeting molecules and uses thereof (2025-10-21),

14. 12441985 - Methods for making insulin in vivo (2025-10-14),

15. 12422367 - Methods for determination of virus titer in a sample using Raman spectroscopy (2025-09-23),

Janssen Biotech, Inc. is a leading biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines in various therapeutic areas including immunology, oncology, neuroscience, infectious diseases, and cardiovascular and metabolic diseases. Backed by Johnson & Johnson, Janssen Biotech strives to make a positive impact on patients' lives by delivering breakthrough treatments and healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

416 Patents

#2 in Horsham, PA

#43 in Pennsylvania

#1,095 in US

#2,205 in the World

Horsham, PA, United States of America

Janssen Biotech, Inc.

Forward Citations = 1,891

632 inventors:

Jinquan Luo (43 out of 51 patents)

Raymond W Sweet (38 out of 47 patents)

Steven Jacobs (36 out of 40 patents)

4. Sheng-Jiun Wu (32 out of 36 patents)

5. Alireza Rezania (31 out of 48 patents)

Please report any incorrect information to support@idiyas.com

Loading…